Does Russia need a treat-to-target initiative?

Rheumatology (United Kingdom)

Volumn 54, Issue 3, 2015, Pages 381-382

  Nasonov, Eugeny L ^a   Karateev, Dmitry E ^a  

^a V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; EDITORIAL; HEALTH CARE SYSTEM; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REIMBURSEMENT; RHEUMATOLOGY; RUSSIAN FEDERATION; SOCIAL BEHAVIOR; STEREOTYPY;

EID: 84941614356     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu156     Document Type: Editorial

References (10)

1. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Jurgens MS, Welsing PM, Jacobs JW. Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission. Clin Exp Rheumatol 2012;30(Suppl 73): S56-63.
3. Vermeer M, Kuper HH, Moens HJ et al. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three year results of the DREAM remission induction cohort. Arthritis Care Res 2013;65:1219-26.
4. Ruderman EM, Nola KM, Ferrell S, Sapir T, Cameron DR. Incorporating the treat-to-target concept in rheumatoid arthritis. J Manag Care Pharm 2012;18:1-18.
5. Pincus T, Castrejón I, Bergman MJ, Yazici Y. Treatto-target: not as simple as it appears. Clin Exp Rheumatol 2012;30(Suppl 73):S10-20.
6. Galushko EA, Erdes ShF, Bazorkina DI et al. [Prevalence of rheumatoid arthritis in Russia (according to epidemiological findings)]. Ter Arkh 2010;82:9-14.
7. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001;30:203-7.
8. Russian National Guidelines for RA. http://www.rheumatolog.ru/files/natrec04.pdf (15 March 2014, date last accessed).
9. Karateev DE, Luchikhina EL, Muravyev YV et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Rheumatol Sci Pract 2013;51: 117-25.
10. Karateev D, Luchikhina E, Gridneva G et al. Subcutaneous (SC) methotrexate (MTX) in patients with rheumatoid arthritis (RA) as a part of ''treat to target'' (T2T) strategy in real practice: preliminary results of REMARCA study. Ann Rheum Dis 2013;72(Suppl 3):893.